Alvotech (ALVO)
5.50
-0.28
(-4.84%)
USD |
NASDAQ |
Oct 12, 16:00
5.50
0.00 (0.00%)
After-Hours: 16:15
Alvotech Profit Margin (Quarterly) : -63.17% for June 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -63.17% |
| March 31, 2026 | 0.97% |
| December 31, 2025 | -65.16% |
| September 30, 2025 | -4.62% |
| June 30, 2025 | 18.49% |
| March 31, 2025 | 99.79% |
| December 31, 2024 | -44.29% |
| September 30, 2024 | -11.07% |
| June 30, 2024 | 32.82% |
| Date | Value |
|---|---|
| March 31, 2024 | -1.76K% |
| December 31, 2023 | -518.0% |
| September 30, 2023 | -1.06K% |
| June 30, 2023 | |
| March 31, 2023 | -1.74K% |
| December 31, 2022 | -1.34K% |
| September 30, 2022 | -45.15% |
| March 31, 2022 | -17.03K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | -1.64% |
| Amgen, Inc. | 23.59% |
| Regeneron Pharmaceuticals, Inc. | 30.23% |
| Anika Therapeutics, Inc. | 10.15% |
| BioCryst Pharmaceuticals, Inc. | 35.92% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -12.30% |
| Return on Invested Capital | -15.48% |
| Gross Profit Margin (Quarterly) | 50.65% |
| Operating Margin (Quarterly) | -11.19% |
| Return on Net Operating Assets | -19.26% |